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Several examples have always illustrated how access to large numbers of biospecimens and associated data plays a
pivotal role in the identification of disease genes and the development of pharmaceuticals. Hence, allowing
researchers to access to significant numbers of quality samples and data, genetic biobanks are a powerful tool in
basic, translational and clinical research into rare diseases. Recently demand for well-annotated and properly-
preserved specimens is growing at a high rate, and is expected to grow for years to come. The best effective
solution to this issue is to enhance the potentialities of well-managed biobanks by building a network.
Here we report a 5-year experience of the Telethon Network of Genetic Biobanks (TNGB), a non-profit association of
Italian repositories created in 2008 to form a virtually unique catalogue of biospecimens and associated data, which
presently lists more than 750 rare genetic defects. The process of TNGB harmonisation has been mainly achieved
through the adoption of a unique, centrally coordinated, IT infrastructure, which has enabled (i) standardisation of
all the TNGB procedures and activities; (ii) creation of an updated TNGB online catalogue, based on minimal data
set and controlled terminologies; (iii) sample access policy managed via a shared request control panel at web
portal. TNGB has been engaged in disseminating information on its services into both scientific/biomedical -
national and international - contexts, as well as associations of patients and families. Indeed, during the last 5-years
national and international scientists extensively used the TNGB with different purposes resulting in more than 250
scientific publications. In addition, since its inception the TNGB is an associated member of the Biobanking and
Biomolecular Resources Research Infrastructure and recently joined the EuroBioBank network. Moreover, the
involvement of patients and families, leading to the formalization of various agreements between TNGB and
Patients’ Associations, has demonstrated how promoting Biobank services can be instrumental in gaining a critical
mass of samples essential for research, as well as, raising awareness, trust and interest of the general public in
Biobanks. This article focuses on some fundamental aspects of networking and demonstrates how the translational
research benefits from a sustained infrastructure.
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Genetic biobanks (GBs) have long been a powerful tool
in basic, translational and clinical research, and in care
practice of rare diseases: indeed GBs allow researchers
the access to significant numbers of quality samples and
associated data. Recent advances in the technology of
molecular biology and genetics, dramatically increasing
the demand for well-annotated and properly preserved
specimens, have contributed to raise the awareness of
the importance of coordinated biobanking activity. The
best and the most effective solution to that demand is to
enhance the potentialities of well-managed biobanks by
building a network.
Here we report a 5-year experience of the Telethon Net-
work of Genetic Biobanks (TNGB), a non-profit organiza-
tion of Italian repositories created to form a unique
catalogue of biological samples and associated data pres-
ently listing more than 750 rare genetic diseases.
The need for networking was recognised in 2008 by
one of the biggest biomedical Italian charity always
committed to the study of genetic diseases, Telethon
Foundation (TF), and was justified by the growing
demand for biological material to develop studies
in rare genetic disorders. Hence the network was
established to (i) centralise very rare samples and data,
(ii) minimise biases potentially arising from heteroge-
neity in the quality of samples by developing standard
procedures and common quality assurance policies, (iii)
enhance collaboration inside the biomedical commu-
nity, and more importantly (iv) promote biobanks
within Patients’ Associations, foster their active partici-
pation and share benefits with them.
The TNGB initiative was also based on the fact
that Telethon had financially supported some genetic
biobanks, as single core facilities, since 1993. There-
fore, TNGB membership was initially limited to the
seven well-managed GBs, but was expanded, over 5-
year project, to other 3 biobanks selected through
specific calls. As the profiles of the TNGB partners
were diverse in their data management, models and
policies, one of the priority goals of TNGB has been
to harmonise a functional net from pre-existing biobanks
by setting out common rules defining network’s ethical,
legal and societal policies as well as standard operating
procedures. TNGB has developed and shared a high-
powered IT infrastructure to standardise and harmo-
nise sample collection and data annotation, as well as
to build a web site to facilitate researcher access and
improve TNGB worldwide visibility. Indeed, although
each GB locally operates in independent way, the
databases of all partners are linked and accessible via
a central web portal.
This article therefore reports some basic aspects
of networking, including governance, managementand IT frameworks to facilitate the establishments
of best practice and standardizations and to ensure
that the interconnected biobanks are acting within
their remit, as well as within the national/inter-
national laws, regulations and recommendations. In
addition, the specific experience of TNGB in the field
of rare-disease-biobank networking also demonstrates
how the translational research benefits from a
sustained infrastructure.
TNGB composition
Currently the network is composed of 10 Biobanks geo-
graphically located in different areas of Italy: while the
founding Biobanks of the Network are seven, the 3
others joined the Network after 1-year pre-admission
period required for adopting and implementing all the
procedures. Because of the peculiarity of the stored
pathologies, 4 biobanks are part of the so called “Joint
Neuromuscular Biobanks” subgroup. The composition
of TNGB is depicted in Figure 1 and the main character-
istics of the individual Biobanks are detailed in the
annexed schema. It is notable that 6 out of 10 Biobanks
have been established in the 70-80’s with the oldest in
1976 and the youngest in 2002, though. Another valu-
able aspect of TNGB composition is that the Host
Laboratories, Departments and Institutions, where the
10 Biobanks have been established, have a longstanding
tradition and internationally recognised expertise in the
diagnosis of, and research into, rare genetic diseases.
Hence, a combination of various activities, supported
by skilled clinicians, pathologists, biochemists and
geneticist, has allowed building, over the course of
several years, these Biobanks preserving well-
documented biospecimens and associated data, which
can also be continuously updated on the basis of
both clinical revisions and more recent scientific
acquisitions.
TNGB governance
The TNGB is governed by the Network Board (NB),
the decision-making body composed of the Coordi-
nator and Biobank Directors. Basically, the NB is
involved in defining the strategic orientation of the
Network and establishing the annual work plan.
The Advisory Board (AB) includes some external mem-
bers, with expertise in legal, ethical and technical issues;
its composition can change over time depending on Net-
work activity evolution.
Telethon Foundation (TF), the funding body, has
checked that the project run smoothly. The assess-
ment of both TNGB and all funded entities, carried
out by the Telethon Scientific Committee for Biobanks,
is based on annual reports summarising activities
and accomplishments.
No. Biobank Name (Acronym) Director
Host Institution
and Location
Establishment 
Year
1
Cell Line and DNA Biobank from 
patients affected by Genetic 
Diseases (IGG-GB)
Mirella Filocamo 
(Coordinator)
IRCCS G. Gaslini 
Genova
1976
2 Galliera Genetic Bank
(GGB)
Chiara Baldo
(Partner 1)
E.O. Ospedali Galliera
Genova
1983
3 Parkinson Institute Biobank
(BPI)
Stefano 
Goldwurm
(Partner 2)
Centro Parkinson 
Istituti Clinici di 
Perfezionamento
Milano
2002
4
Cell lines and DNA bank of Rett 
syndrome, X-linked mental 
retardation and other genetic 
diseases (biobankUNISI)
Alessandra 
Renieri
(Partner 3)
Policlinico Le Scotte 
Università di Siena 
Siena
1998
5 Neuromuscular Bank of Tissues 
and DNA samples (NMTB) 
Corrado Angelini 
(Partner 4)
Dipartimento
Neuroscienze
Università di Padova 
Padova
1982
6
Bank of DNA, Cell lines and 
Nerve-Muscle-Cardiac tissues 
(biobankNMD-Milan)  
Maurizio Moggio
(Partner 5)
Fondazione IRCCS Ca' 
Granda Ospedale 
Maggiore Policlinico 
Milano
1986
7
Cell, tissues and DNA from 
patients with Neuromuscular 
Diseases (NeuMD)
Marina Mora 
(Partner 6)
Istituto Neurologico C. 
Besta Fondazione
IRCCS Milano
1986
8 Genomic Disorder Biobank
(GDB)
Giuseppe Merla 
(Partner 7)
IRCCS Casa Sollievo 
della Sofferenza 
S. Giovanni Rotondo
2002
9 Naples Human Mutation Gene 
Biobank (NHMGB)
Luisa Politano 
(Partner 8)
Cardiomiologia e 
Genetica Medica
2a Università  di Napoli 
Napoli
1991
10
Cell Line and DNA Bank of 
Paediatric Movement Disorders 
(PMD)
Barbara 
Garavaglia
(Partner 9)
Istituto Neurologico C. 
Besta Fondazione 
IRCCS Milano
2002
Legend: Partners#1-7 are the 7 founding Biobanks, #8-10 joined the Network after 1-year pre-admission
period
NAPOLI
S.GIOVANNI 
ROTONDO
SIENA
GENOVA
MILANO
PADOVA
Figure 1 Geographical location of the genetic biobanks in Italy. Yellow triangle denotes biobanks, the black outline marks the “Joint
Neuromuscular Biobanks” subgroup. Composition and institutional affiliation of the Biobanks are reported in the annexed schema on the left.
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grant by the NB among the Biobank Directors, plays a
central role and maintains the contacts with the Network
Board, the Advisory Board and the Telethon Scientific
Office. The Coordinator is supported by a Coordinator
Emeritus having the main tasks of promoting the Network
and interacting with Patients’Associations.
In case of particular controversies, an external commit-
tee, the Approval/Appeal Panel (AP), can be convened for
a third-party opinion. Typically, the panel composition
includes one AB member, one from the Telethon Biobank
Committee, and a third external member selected among
the International Scientific Community. The AP com-
position is concerted with TF, in accordance with
peer-review-based procedures, and depends on the
type of the controversial issue. Figure 2 is a graphical
representation of the main TNGB governance bodies.
Relationships among the TNGB partners including
rules for decision-making processes, ethical guidelines,
activities, policies, expected benefits, and undertaken
duties have been laid down in the TNGB Charter [1].Harmonisation and standardisation: the role of the
coordination office
The coordination office (CO) is involved with day-to-day
operational aspects to guarantee a harmonised manage-
ment of the Network through the standardisation of all
the main activities.
Standard operating procedures (SOPs) for sample
collection, processing and storage employed across
the TNGB Partners have been shared with only minor
local modifications and made available on the TNGB
web site. Standardisation has been mainly achieved
through database management, minimal data set, con-
trolled terminologies, sample access policy, common
informed consent form, and quality control tools
aimed at identifying potential bias due to sample
processing as well as variables unrelated to the dis-
ease being studied. Harmonisation of policies, SOPs
and documents is however an ongoing activity: in-
deed, all documents are continuously reviewed to be
compliant with both national and European guidelines
and directives.
Figure 2 Graphical representation of the TNGB governance bodies. Legend: P = Partner; JNB = Joint Neuromuscular Biobanks.
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lity amongst the TNGB’s members, CO has also
avoided inefficiencies potentially arising from indi-
vidual initiatives.
IT infrastructure
The IT infrastructure, developed by SoftWerk
(Genova, Italy) [2], is the management tool of the
network. Each TNGB Partner has been provided with
a small server machine with a free operating system
(GNU/Linux) with open source software (LAMP
stack solution) and preinstalled web-like applications
accessible to the TNGB members regardless of their
operating system. The servers provide local storage
and backup; in addition, to execute schedule off-site
backups and to feed data to the central database
consolidator, they are connected to the central net-
work servers by virtual private network (VPN)
techniques.
Hence, sharing an IT platform has not meant a
loss in autonomy as the associated biobanks, residing
within their own host institution, manage the core
biobank data by optional modules adapted to needsand peculiarities of each biobank. The IT system
automatically aggregates from each local database a
minimum coded dataset which is published on the
TNGB web site in a single online catalogue.
Data safety is guaranteed by server redundancy
and automated cyclic on-site, off-site and cross-site
encrypted backups both on optical media and remote
servers through Secure Socket Layer (SSL) 128 bit
encrypted channels.Web access to the network
The Network has published a web site [3] which
provides access to the public pages, the Network’s
intranet and the Request Control Panel.
The public area contains general network informa-
tion and contacts, online aggregated catalogue
and a search engine for the aggregated biobank
data, login reserved area, TNGB official documents
(The Charter, Biobank guidelines, SOPs), dis-
tinct agreements between TNGB and Patients’ Asso-
ciations, and list of publications acknowledging
TNGB services.
Figure 3 Classification of the diseases into large subgroups.
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The Biobanks of the Network collectively preserve
75,900 biospecimens deriving from more than 750 dif-
ferent genetic defects. As shown in Figure 3, a concise
classification of the diseases includes: Cardiovascular
disorders; Chromosome aberrations; Craniofacial disor-
ders; Deafness; Dermatologic disorders; Endocrine disor-
ders; Genomic disorders; Haematological diseases;
Intellectual disability; X-linked intellectual disability; Meta-
bolic disorders; Neuromuscular disorders; Neurologic dis-
orders; Movement disorders; Ophthalmologic disorders;
Primary Cardiomyopathies; Rare Tumors; Renal disorders;
Rett Syndrome; Skeletal dysplasias; White matter disorders.
Figure 4 reports the main types of biospecimens,
stored in the Biobanks, which include foetal and adult
cell lines (amniocytes, trophoblast cells, fibroblasts, myo-
blasts, lymphoblasts and T-lymphocytes activated with
IL-2), peripheral blood lymphocytes, muscle and nerve
tissues, tissues derived from foetal loss, DNA/RNAFigure 4 TNGB biospecimen typologies. Legend: Others = blood, leucocy
nerve, skin, foetal tissues. Cell lines = fibroblasts, EBV-lymphoblasts, lymphocytesamples, sera/plasma and whole blood samples, and iPS
cells.
Sample management
Storage
The incoming samples are managed by each partner and
locally recorded in the respective individual databases.
The samples will be processed for the storage only with
the written informed consent of the patients or their
parents or legal guardian in cases where an individual is
considered unable to give consent. In addition, a mater-
ial transfer agreement (MTA-in), signed by the referring
clinician, should accompany each sample and include
at least the minimum TNGB-shared data set, that is
donor’/patient’s generalities (name, date of birth, a-
ddress, ethnic origin, gender), phenotype (affected/not
affected), essential anamnestic data (presence of consan-
guinity and/or familiarity, tissue and/or organ anomalies,
laboratory test anomalies, etc.), diagnosis data (modality,tes in DMSO, T-lymphocytes + il-2, liquor, serum/plasma. Tissues =muscle,
s, myoblasts, amniocytes, trophoblast cells, iPS.
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data of collection, etc.).
To ensure a uniform codification and classification,
the diseases of the catalogue are defined by OMIM (On-
line Mendelian Inheritance in Man) number, Orpha
(Orphanet classification of Diseases) number, and ICD
(International Classification of Diseases) code.
Sample access policy
Basic rules to manage access to collections and related
data are shared among the TNGB partners and applied
to all researchers, including the Biobank Staff. General
criteria include: (i) guarantee that an adequate aliquot of
sample be saved for patients and/or their relatives,
aimed at potentially retrospective analyses; (ii) sample
distribution only to qualified professionals working at re-
search or medical institutions engaged in health-related
research or health care; (iii) appropriate justification forFigure 5 Policy for sample distribution.sample use; (iv) sample transfer only if the material
transfer agreement form has been signed from Principal
Investigator; (v) project design in agreement with TNGB
mission and policies.
TNGB has also recently implemented and adopted a
cost recovery system aimed at making biobanks financially
semi-independent. Briefly, researchers are requested to
partially cover the cost of some basic procedures related
to the TNGB distribution services, in addition to the ship-
ping costs.
As shown in Figure 5, the procedure of outgoing samples
occurs entirely through TNGB web portal: for requesting
samples, the users, including Biobank staff, must first
register at the relevant web-page. After authentication,
users can submit their request filling in the online “Re-
quest submission form”. The submission implies that
users provide some essential information including a brief
description of the project and research-grant sponsor.
Filocamo et al. Orphanet Journal of Rare Diseases 2013, 8:129 Page 7 of 11
http://www.ojrd.com/content/8/1/129Users can select samples from the catalogue as a specific
diagnosis classified according to OMIM, Orpha, ICD
codes, or alternatively, by configuring a query for some
their attributes such as type of sample, gender, phenotype,
type of diagnosis, etc. Alternatively, users can submit the
request by describing the main characteristics of the sam-
ples necessary for their study. The so called “open request”
implies that users will be supported by the relevant
Biobank Staff to select the most suitable samples. Once
the request is centrally submitted at the Request Control
Panel (RCP) and has obtained the consensus of all Net-
work Board, the coordination office passes it on the
sample-holding biobank’s Staff, who replies with a proper
Material Transfer Agreement form (MTA-out). The as-
signment of the concerned Biobank(s) requires at the lat-
est 5 working days for consistent requests. By signing this
form the user undertakes to respect the TNGB’s rules and
policies. The main MTA-out issues include: scientific
manager; project and research sponsor; type and quantity
of concerned samples; citation in acknowledgements;
transfer of samples to third parties; communication of sci-
entific results; cost recovery and shipping cost.
The RCP access, protected by password, is available
for Biobank Directors who can share, process, monitor
and update all TNGB requests.
The RCP is, therefore, an innovative tool which has
put into practice the harmonisation process through the
management and the monitoring of all TNGB requests.
Most importantly, RCP has also avoided duplication of
research efforts on very rare and precious biospecimens.
Figure 6 reports details concerning the large amount
of the incoming and outgoing samples from 2008 to
2012. In particular, as shown in the diagram on the left
(Figure 6A), a total of 25,712 samples and data have
been biobanked with an annual average of 5,142 (ranging0
1000
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Tissues 934 817 752 627 785
Cell lines 778 722 788 1013 879
DNA/RNA 2653 2258 2759 3082 3271
A
Figure 6 Sample workflow. The graphics illustrate the incoming (A) and
leucocytes in DMSO, T-lymphocytes + il-2, liquor, serum/plasma. Tissues =mu
lymphocytes, myoblasts, amniocytes, trophoblast cells, iPS.from 4,010 to 6,283). In the same vein, the outgoing sam-
ple volume had a clear tendency to increase (Figure 6B),
being totally 27,086 with an annual average of 5,417 ran-
ging from 3,731 to 7,714. To be also noted the significant
increase of the variety of the incoming samples (Figure 6A)
which reflects a Network particularly careful to satisfy
current and future demands of the genomic and proteo-
mics studies requiring vast amounts of samples.
Request typology
Over the past 5 years, national and international scien-
tists have extensively used the TNGB with different pur-
poses, as well as, patients and patients’ family members
have been able to rely on the TNGB services.
The activities related to this service can be broken into
three main categories:
1) “research”: in this field the Network supported 784
research projects by providing several thousand of
samples;
2) “diagnosis”: this category refers to a service that is
an added value of the TNGB as it provides access to
clinicians who require storing samples from
“undiagnosed” patients aimed at future diagnoses. In
this field the TNGB fulfilled a total of 441 requests
even though a considerable number of samples from
patients without diagnosis still remains in each
Biobank;
3) “family”: TNGB has also supported members from
18 families at risk for a rare disease. These users,
being aware of the Biobank storing the sample(s)
from the respective patients’ index case, directly
contacted therefore the concerned Biobank and
requested sample(s) to be used for genetic
counselling including the prenatal diagnosis.0
1000
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7000
8000
2008 2009 2010 2011 2012
Others 12 12 83 65 119
Tissues 417 456 256 427 240
Cell lines 259 437 434 458 570
DNA/RNA 3043 4185 4896 3932 6785
B
outgoing (B) flow of the TNGB samples. Legend: Others = blood,
scle, nerve, skin, foetal tissues. Cell lines = fibroblasts, EBV-lymphoblasts,
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Published and/or non-published analytical results obtained
using the Biobank samples are gathered through the rele-
vant “Confirmation of sample use” form periodically
sent to TNGB users. During the 5-year period more
than 250 scientific publications resulted from research
conducted thanks to the services provided by the 10
Biobanks, which were formally acknowledged in the
proper section of the related manuscripts, accordingly
[4]. Figure 7 is the graphical representation of the scien-
tific production resulting from the distribution service
by Biobank.
By using TNGB samples, impressive results were
achieved in the field of rare diseases and, whenever of
clinical interest, the priority was to promptly return them
to the patients/donors. The main findings included: dis-
covery and/or characterisation of new syndromes; new
gene identification; molecular and functional studies; epi-
demiologic studies; method set up; genotype/phenotype
correlation studies; therapeutic studies; stem cells and
clinical applications. Retrospective diagnoses were also
reached in several patients. Additional file 1: Table S1 re-
ports some significant examples per result-category for0
5
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IGG-GB GGB BPI
biobankUNIS
I
NMTB
2008 12 5 9 1 3
2009 10 10 6 3 7
2010 10 8 7 5 5
2011 7 8 10 5 10
2012 16 6 3 2 9
2008 2009
Figure 7 Scientific production resulting from the 10 Biobanks’ service
2010 (GDB) and 2011 (NHMGB, PMD), respectively. To be noted that the Bieach Biobank and shows how patients and, by extension,
the healthcare have benefited from the research outcomes
conducted with the TNGB samples.
Ethical, legal and social issues (ELSI)
Given the quantitative and qualitative value of the infor-
mation attached to the biobank’s sample, it is imperative
that TNGB protects the patients/donors’ confidentiality
according to national and international regulations and
recommendations [5-10]. In the same vein, the possibil-
ity of tracing the sample back to its patient/family/donor
is also essential in the event of scientific results of use to
the donor. Therefore, the registration of the samples is
performed in identifiable mode, which means coding
biological material for research purposes but making the
link to their source possible through the use of a code
known to Biobank Director and authorised staff only.
Informed consent
Consent form and patient information sheet, shared by
TNGB to seek the permission for biobanking from the
donors or their legal representative, disclose all aspects
related to the handling of the samples and data2008
2009
2010
2011
2012
biobankNMD NeuMD GDB* NHMGB* PMD*
5 3
7 6
5 7 0
7 11 2 1 1
8 6 0 3 4
2010 2011 2012
s. Legend: asterisk denotes that the Biobank joined the network in
obank acronyms are defined in the annexed schema of Figure 1.
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ple may be used for further investigations of an exclu-
sively diagnostic and/or research nature in the field of
the concerned pathology only, and never for direct
profit; if the sample is to be used in a different project a
new consent will be sought; (ii) results: it is explained
how the potential benefits derived from the use of the
sample can positively impact upon the health of the in-
dividual and/or the entire community; (iii) confidential-
ity: the procedures for handling the data to ensure
protection of privacy are illustrated; (iv) service guaran-
tee: it has to be clarified that while handling and storage
of the biological material are the responsibility of the
Biobank Director, other accidental damage to the sample
can unpredictably occur; (v) consent withdrawal: it is
made explicit that consent can be withdrawn at any time
removing the sample and relevant information. These
aspects were also in line with other studies. [11].
The subject who has received the information has the
possibility to take separate decisions regarding whether or
not to (i) authorise the preservation; (ii) authorise the use
of sample for scientific research; (iii) wish to be informed
about the results deriving from continuing research.
After signing the consent form, the subject receives a
copy countersigned by the person responsible for the
Biobank as a guarantee of the respect for the statements.
Concerning the samples stored in the past without in-
formed consent, in accordance with ESHG (European
Society of Human Genetics) document [12], they are
used in an identifiable manner guaranteeing confidenti-
ality according to the rules of professional deontology
and existing regulations, without the obligation to ren-
der the samples anonymous, in order to be able to make
any diagnosis and/or important result available to bio-
logical patients’ family members.
Patients’ Associations
The TNGB has developed a close relationship with Pa-
tients’ Associations since its inception: indeed, theirFigure 8 Agreement with patients’ association: tasks of the parties.representative has always been active part of the Advis-
ory Board. This has enabled them to be involved in the
drafting of policies and procedures for the improvement
of the TNGB infrastructure including ethical issues such
as transparency, consent, privacy, confidentiality, use and
transfer of samples.
Alongside this, several meetings and workshops have
been organised with the main aim to raise awareness,
trust and interest in Biobanks as well as to introduce
patients and their families to the concept of this
bioresource as an effective service for collecting and
centralising rare samples for specific research projects.
In this respect, the Coordinator Emeritus has played a
major role with the active collaboration and support of
UNIAMO [13] (Italian Federation of about 100 Associa-
tions of patients with rare diseases) and other national
Associations. The involvement of patients and families
has proved to be instrumental in both gaining a critical
mass of samples, that is essential for research into very
rare diseases [14], and ensuring that patients’ needs and
expectations in the field of biobanking be taken into due
consideration.
Through this dissemination activity at national level,
the interest in the Biobanks’ services is enormously
increased among patients and their families. In fact, a
framework agreement has been formalised between
Telethon and UNIAMO to be the basis of each agree-
ment between one of the Biobanks of the Network and a
specific Patients’ Association. Currently, 6 agreements
[15] have been signed with the first one formalised in
2009 and annually confirmed up to now.
To our knowledge, this type of agreement, defining
rules and tasks of the parties, viz. Genetic Biobanks and
Patients’ Association, is unique at national and inter-
national levels and aims at supporting families with
biobanking in a harmonized environment that ensures
quality and proper use of the samples, as well as individ-
uals’ confidentiality throughout the entire process (Figure 8).
But, more importantly, patients’ samples, being listed in
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who visit the web page. Another equally important aspect
is that the Associations can play an active part within this
framework agreement by promoting as well as cofounding
specific projects on their collections. In this respect, “Ring
14 Association”, the first to sign the agreement in 2009,
has currently two ongoing projects.
Final considerations
The results of first 5 years of TNGB activities have con-
firmed the validity of this management model and more
importantly showed that the Telethon’s investment policy
in Biobanks, started in 1993, has so far been effective.
The Network is continuing to expand centralising a
broader range of very rare disease types and recently
partnering with EuroBioBank [16] which has been the
first European network of genetic biobanks of rare dis-
eases. In addition, since its inception TNGB, fulfilling
the requested quality criteria, joined the pan-European
research infrastructure BBMRI [17] as associated mem-
ber. Within this framework, the Network also was one
of the ten prototypes selected by Technopolis Group for
a short/long term impact analysis, commissioned by
BBMRI, aimed to support discussions on the sustainabil-
ity of the future BBMRI research infrastructure [18].
Currently, TNGB is actively involved in the constitution
of the Italian Node (BBMRI-IT).
The qualifying aspects of the TNGB can be summarised
as follows: (i) the rigorous selection criteria adopted by
Telethon for choosing the Biobanks to receive funding
along with a thorough annual report to revise the budget:
this method has been greatly stimulating and has provided
the Biobanks direction for ameliorative actions to be taken
in terms of services, quality management and information
dissemination; (ii) the sensitivity of Telethon Scientific
Office to deal with some of the issues raised over time:
thanks to this modus operandi TNGB has achieved con-
siderable progress and, at the same time, it has gradually
developed a common culture about biobank governance
system; (iii) the special attention paid to patients and fam-
ilies with genetic disorders: these concerted activities be-
tween TNGB, Telethon Scientific Office and Patients’
Associations have increased both the dissemination of
knowledge about the Biobank key role among the com-
munity as well as the use of their services.
Recently TNGB has become one of the associated part-
ners of the European RD-connect project aimed at
connecting databases, registries, biobanks and clinical bio-
informatics for rare disease (RD) research [19]. Therefore
TNGB is engaged in the process of building a global
harmonised infrastructure to efficiently distribute quality
controlled samples and associated data for the study of
RD in a protected ethical and legal framework. In connec-
tion with this, TNGB is also focused on improvingservices and quality management of each individual
Biobank of the Network through the implementation of a
certification program by applying International
Organization for Standardization (ISO) 9001 and ISO
15189 which include specific indicators for Genetic
Biobanks (“Standard criteria for quality management for
Genetic Biobanks”, developed by Italian Society of Human
Genetics [20]).
Concerning the future of TNGB, recent advances in
next-generation sequencing technologies provide unpre-
cedented opportunities for using the current Network to
encompass a broader range of disease types. However,
the potential of the new high-throughput genotyping
technologies raises ethical issues not only including the
consent that currently is not “broad” but restricted to
that specific pathology of the patient, but also the man-
agement of the excessive amount of information, in par-
ticular of the so called “incidental findings” [21]. In
consideration of this, legal and ethical aspects still need
to be addressed. Based on a longstanding experience of
TNGB, a collaboration with experts, including Italian
data protection Authority, has started with the aim to
accelerate the definition of national regulations for Gen-
etic Biobanks.
Additional file
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